The Company's full financial statements and related MD&A for the first quarter ended September 30, 2024, are available at www.inmedpharma.com, www.sedar.com and at www.sec.gov.
Alzheimer’s changed the couple’s routine, but not their fight to keep going. Together, David and Pamela are awareness advocates for the Alzheimer’s Association. They’ve met with representatives on ...
Most discontinued anti-tau antibodies (red) targeted tau’s N-terminus. Of the antibodies currently in trials (green), bepranemab and E2814 presented results at CTAD, while JJ-63733657/posdinemab and ...
A European regulatory committee now recommends approval of the Alzheimer's treatment lecanemab a few months after rejecting ...
Researchers at Texas A&M University have developed a nasal spray shown to delay disease progression in animals -- fueling ...
A multitude of genes have been linked to the development of Alzheimer's disease. Specifically how those genes might influence ...
In the world of health, Novo Nordisk stops insulin pen production, Trump's potential health appointments draw attention, and ...
A key regulatory committee sided against the drug this summer. But an appeal from Eisai appears to have worked, teeing ...
A European regulatory committee now recommends approval of the Alzheimer’s treatment lecanemab a few months after rejecting ...
Researchers have developed a simple model system that can be used to break down fibrils -- the cause of numerous disorders including Alzheimer's and Parkinson's disease -- into their constituent ...
The Associated Press noted that one of FDA’s requirements calls for drug companies to show on-screen text about side effects while the audio information plays. RELATED: Eli Lilly's Alzheimer's drug ...
The European Medicines Agency has flipped its stance on Eisai and Biogen’s Alzheimer’s treatment Leqembi, recommending ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback